Insulin pump therapy and glucose control during Ramadan fasting in an adolescent with type 1 diabetes: from an open-loop sensor-augmented pump therapy with predictive low-glucose management to an advanced hybrid closed-loop system

Wannes, Selmen; Qusayer, Dhai Al; Abed, Sameh El; Fredj, Manel Ben

doi:10.1007/s00592-023-02049-4

Cited by 6 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latest data on diabetes and technology during Ramadan in 2023 are presented in Table 4 . 24 30 31 32 33 34 35 These are briefly summarized here. AlGhatam et al in a randomized pilot study investigated the effects of different insulin pump settings on TIR.…”

Section: Highlights Of the Literaturementioning

confidence: 99%

“…Wannes et al assessed the efficacy and safety of a hybrid closed-loop (HCL) system during RF in a pediatric cohort with T1D. 32 Glucose control outcomes in older children and adolescents aged 8 to 16 years with automated insulin delivery for T1D were analyzed during Ramadan and 1 month before Ramadan. Participants on MiniMed standard HCL (670G) or advanced HCL (780G) systems of Medtronic were categorized as fasting or nonfasting.…”

Section: Highlights Of the Literaturementioning

confidence: 99%

“…24 Also, Wannes et al described insulin pump therapy and glucose control during RF in a child with T1D. 35 This illustrates progressing from an open-loop sensor-augmented pump therapy with predictive low-glucose management to an AHCL system. The child fasted for two successive Ramadan seasons under two innovative insulin administration technologies regarding diabetes management.…”

Section: Highlights Of the Literaturementioning

confidence: 99%

See 2 more Smart Citations

Diabetes and Ramadan Fasting (2023): The Year in Review

Abusahmin,

Abdelgadir,

Eledrisi

et al. 2024

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Introduction We aimed to provide an overview of the global literature production on diabetes and Ramadan in the past year (2023). Materials and Methods This is a narrative, nonsystematic review of the international literature from two major medical online databases (PubMed and Google Scholar) in 2023. The search term “Diabetes AND Ramadan fasting” was used, and the relevant literature was narrated in a concise thematic account. Results The publications spanned a vast array of topics related to diabetes and Ramadan fasting (RF), including physiology and nutrition, risk assessment stratification tools and their validation, assessments of safety and efficacy profiles of older and newer diabetes therapies, diabetes education, use of advanced technology for the treatment, and monitoring and impact on pregnancy. Some reports covered the interaction between Ramadan and COVID-19 concerning diabetes, pregnancy, complications, and unique characteristics of diabetes and fasting by young and older people. Conclusion The current narration presents this year's global scholarly production on the safety of fasting practices, care models, and patients' experiences and perspectives.

show abstract

Section: Highlights Of the Literaturementioning

confidence: 99%

Section: Highlights Of the Literaturementioning

confidence: 99%

Section: Highlights Of the Literaturementioning

confidence: 99%

See 1 more Smart Citation

Diabetes and Ramadan Fasting (2023): The Year in Review

Abusahmin,

Abdelgadir,

Eledrisi

et al. 2024

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

show abstract

“…A comparison between the use of a PLGS system during Ramadan in 2021 and the use of the MiniMed™ 780G system during the following Ramadan season in 2022 showed that the AHCL system was associated with better glycaemic outcomes and a reduced time spent in hypoglycaemia. Due to the high percentages of fat in some traditional Ramadan-specific foods, supplementation with an extra bolus (15% of the previously announced carbohydrates) 90 min after the evening meal was recommended to counteract late postprandial hyperglycaemia [ 46 ]. No DKA or SH was detected during and before Ramadan with AHCL, but significantly better results in terms of hypoglycaemia were also obtained with the MiniMed™ 780G system, with TBRs of 0% vs 2% ( p < 0.01).…”

Section: Summary Of Case Reportsmentioning

confidence: 99%

Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780G™ in Children, Adolescents and Young Adults: A Systematic Review

Passanisi,

Lombardo,

Mameli

et al. 2023

Diabetes Ther

View full text Add to dashboard Cite

The MiniMed™ 780G is a second-generation automated insulin delivery system that implements a modified proportional–integral–derivative algorithm with some features of an MD-Logic artificial pancreas algorithm. The system may deliver automatic correction boluses up to every 5 min, and it allows the user to choose between three glucose target setpoints (100, 110 and 120 mg/dL). We aimed to review the current evidence on this device in children, adolescents, and young adults living with type 1 diabetes. We screened 783 papers, but only 31 manuscripts were included in this review. Data on metabolic outcomes show that this system is safe as regards severe hypoglycaemia and diabetic ketoacidosis. The glycated haemoglobin may drop to levels about 7%, with CGM reports showing a time in range of 75–80%. The time above range and the time below range are within the recommended target in most of the subjects. Few studies evaluated the psychological outcomes. This system seems to be more effective than the first-generation automated insulin delivery systems. The MiniMed™ 780G has been associated with an improvement in sleep quality in subjects living with diabetes and their caregivers, along with an improvement in treatment satisfaction. Psychological distress is as reduced as the glucose control is improved. We also discuss some case reports describing particular situations in clinical practice. Finally, we think that data show that this system is a further step towards the improvement of the treatment of diabetes as concerns both metabolic and psychological outcomes.

show abstract

“…The MiniMed 780G system has shown efficacy and safety during the month of Ramadan in a randomized controlled trial 10 and in a case report 11 . Both studies, however, were conducted in highly controlled settings and for a proper performance and safety profile of the MiniMed 780G system during Ramadan unbiased real‐world evidence is needed.…”

Section: Introductionmentioning

confidence: 99%

The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan

Al‐Sofiani,

Petrovski,

Al Shaikh

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo report on the effectiveness and safety of the MiniMed 780G automated insulin delivery system in real‐world users during the month of Ramadan.Materials and MethodsCareLink Personal data were extracted from MiniMed 780G system users from the Gulf region. Users were included if they had ≥10 days of sensor glucose data during the month of Ramadan 2022 as well as in the month before and after. For the main analysis, continuous glucose monitoring endpoints were aggregated per month and were reported by time of day (daytime: 05.31‐18.00 h, and night‐time). Additional analyses were performed to study the pace at which the algorithm adapts.ResultsGlycaemic control was well kept in the 449 included users (mean sensor glucose = 152.6 ± 18.7 mg/dl, glucose management indicator = 7.0 ± 0.4%, time in range = 70.7 ± 11.0%, time below 70 mg/dl = 2.3 ± 2.3%). Albeit some metrics differed from the month before (p < .0001 for all), absolute differences were very small and considered clinically irrelevant. During Ramadan, there was no increased risk of hypoglycaemia during daytime (time below 70 mg/dl = 2.3 ± 2.4%), time in range was highest during daytime (80.0 ± 10.7%, night: 60.4 ± 15.3%), while time above 180 mg/dl was highest during night‐time (37.3 ± 16.3%, day: 17.7 ± 10.7%). The algorithm adapted immediately upon lifestyle change.ConclusionThe MiniMed 780G automated insulin delivery system is effective, safe and fast in adapting to the substantial changes that occur in the lifestyle of people with type 1 diabetes during Ramadan.

show abstract

Insulin pump therapy and glucose control during Ramadan fasting in an adolescent with type 1 diabetes: from an open-loop sensor-augmented pump therapy with predictive low-glucose management to an advanced hybrid closed-loop system

Cited by 6 publications

References 5 publications

Diabetes and Ramadan Fasting (2023): The Year in Review

Diabetes and Ramadan Fasting (2023): The Year in Review

Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780G™ in Children, Adolescents and Young Adults: A Systematic Review

The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan

Contact Info

Product

Resources

About